D K Wysowski

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, Maryland 20857, USA
    Diabetes Care 26:1852-5. 2003
  2. ncbi An analysis of reports of depression and suicide in patients treated with isotretinoin
    D K Wysowski
    Division of Drug Risk Evaluation I, Office of Post Marketing Drug Risk Assessment, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    J Am Acad Dermatol 45:515-9. 2001
  3. ncbi Comparison of reported and expected deaths in sildenafil (Viagra) users
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Am J Cardiol 89:1331-4. 2002
  4. ncbi Use of menopausal hormones in the United States, 1992 through June, 2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Pharmacoepidemiol Drug Saf 14:171-6. 2005
  5. ncbi Sex and age differences in serum potassium in the United States
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Clin Chem 49:190-2. 2003
  6. ncbi Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions
    D K Wysowski
    Office of Post-Marketing Drug Risk Assessment, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Am J Gastroenterol 96:1698-703. 2001
  7. ncbi Trends in outpatient prescription drug use and related costs in the US: 1998-2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, Rockville, Maryland, USA
    Pharmacoeconomics 24:233-6. 2006
  8. ncbi Use of medications for erectile dysfunction in the United States, 1996 through 2001
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, Maryland, USA
    J Urol 169:1040-2. 2003
  9. ncbi Use of inhalant medications with and without chlorofluorocarbon propellants in the United States, 1996-2000
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    J Allergy Clin Immunol 110:51-3. 2002
  10. ncbi Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Anesthesiology 105:1047-51. 2006

Collaborators

Detail Information

Publications14

  1. ncbi Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, Maryland 20857, USA
    Diabetes Care 26:1852-5. 2003
    ..To describe the use of oral antidiabetic drugs for management of type 2 diabetes in the U.S. from 1990 through 2001...
  2. ncbi An analysis of reports of depression and suicide in patients treated with isotretinoin
    D K Wysowski
    Division of Drug Risk Evaluation I, Office of Post Marketing Drug Risk Assessment, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    J Am Acad Dermatol 45:515-9. 2001
    ..The Food and Drug Administration (FDA) has received reports of depression and suicide in patients treated with isotretinoin...
  3. ncbi Comparison of reported and expected deaths in sildenafil (Viagra) users
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Am J Cardiol 89:1331-4. 2002
  4. ncbi Use of menopausal hormones in the United States, 1992 through June, 2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Pharmacoepidemiol Drug Saf 14:171-6. 2005
    ....
  5. ncbi Sex and age differences in serum potassium in the United States
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Clin Chem 49:190-2. 2003
  6. ncbi Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions
    D K Wysowski
    Office of Post-Marketing Drug Risk Assessment, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Am J Gastroenterol 96:1698-703. 2001
    ....
  7. ncbi Trends in outpatient prescription drug use and related costs in the US: 1998-2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, Rockville, Maryland, USA
    Pharmacoeconomics 24:233-6. 2006
    ..CONCLUSIONS: These data indicate a large increase in the US over a short time period in dispensed outpatient prescriptions and their associated retail costs...
  8. ncbi Use of medications for erectile dysfunction in the United States, 1996 through 2001
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, Maryland, USA
    J Urol 169:1040-2. 2003
    ..The data indicate the wide adoption and use of sildenafil for erectile dysfunction...
  9. ncbi Use of inhalant medications with and without chlorofluorocarbon propellants in the United States, 1996-2000
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    J Allergy Clin Immunol 110:51-3. 2002
  10. ncbi Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Anesthesiology 105:1047-51. 2006
  11. ncbi Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, White Oak, Bldg 22, Room 3424, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Arch Intern Med 167:1414-9. 2007
    ..Warfarin sodium is widely used and causes bleeding; a review might suggest the need for regulatory action by the US Food and Drug Administration (FDA)...
  12. ncbi Statin use and the risk of breast cancer
    Patricia Beck
    Saskatchewan Health, Population Health Branch, 3475 Albert Street, Regina SK S4S 6X6, Canada
    J Clin Epidemiol 56:280-5. 2003
    ..More studies are needed to determine if short-term statin use and statin use with long-term HRT exposure increases postmenopausal BRCA risk. Published by Elsevier Science Inc...
  13. ncbi Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients
    James L Mills
    National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, 6100 Building Room 7B03, Bethesda, MD 20892, USA
    J Pediatr 144:430-6. 2004
    ..We investigated whether they were at increased risk of death from other conditions, particularly preventable conditions...
  14. ncbi Analyzing prescription drugs as causes of death on death certificates
    Diane K Wysowski
    Public Health Rep 119:520. 2004